Baird Starts Audentes Therapeutics (BOLD) at Underperform
Tweet
Share
E-mail
Get Alerts BOLD Hot Sheet
Price: $2.83 +1.80%
Rating Summary:
3 Buy, 12 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
3 Buy, 12 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Baird analyst Madhu Kumar initiates coverage on Audentes Therapeutics (NASDAQ: BOLD) with a Underperform rating and a price target of $10.00.
For an analyst ratings summary and ratings history on Audentes Therapeutics click here. For more ratings news on Audentes Therapeutics click here.
Shares of Audentes Therapeutics closed at $26.35 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Raymond James Starts SpyGlass Pharma (SGP) at Outperform
- Oppenheimer Starts Carriage Services (CSV) at Outperform
- JPMorgan Assumes salesforce.com (CRM) at Overweight, 'Overblown Concerns'
Create E-mail Alert Related Categories
Hot New Coverage, New CoverageRelated Entities
Robert W BairdSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
